

## Review Form 1.6

Journal Name:	<a href="#">International Research Journal of Oncology</a>
Manuscript Number:	Ms_IRJO_84503
Title of the Manuscript:	<b>A Case of Lung Cancer with Covid-19: Symptom and Imaging Analysis -Dilemma of Managing Multiple Comorbidities</b>
Type of the Article	<b>Case report</b>

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalirjo.com/index.php/IRJO/editorial-policy> )

## Review Form 1.6

### PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<ol style="list-style-type: none"><li>1. There are many reports on patients having both lung cancer and COVID-19; there are even original articles on the topic (for example a work by Luo et al. doi: 10.1016/j.annonc.2020.06.007). Therefore, I do not believe that this is a rare report or an interesting report.</li><li>2. The manuscript needs to be edited for errors in grammar and vocabulary.</li><li>3. In the introduction and discussion, more focus should be put on the effect of having diabetes or lung cancer and the treatment of COVID-19.</li></ol>	
<b>Minor</b> REVISION comments	<ol style="list-style-type: none"><li>1. In last sentence of the abstract, the authors have mentioned that "We present this case to establish the best possible treatment plan for asymptomatic COVID patients with other co-morbidities and respiratory symptoms"; the patient that they reported had symptoms and was not asymptomatic.</li><li>2. The abbreviations should be written in its complete format for the first time they are used; for example, COVID-19, SARS-CoV-2, WHO and RR are just brought in its abbreviated format.</li></ol>	
<b>Optional/General</b> comments	-	

### PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

### Reviewer Details:

Name:	Erfan Taherifard
Department, University & Country	Shiraz University of Medical Sciences, Iran